Drug profile · INN
daunorubicin hydrochloride
DAUNORUBICIN HYDROCHLORIDE
daunorubicin hydrochloride (DAUNORUBICIN HYDROCHLORIDE) is a dna topoisomerase ii alpha inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — daunorubicin hydrochloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
daunorubicin hydrochloride (DAUNORUBICIN HYDROCHLORIDE) is a dna topoisomerase ii alpha inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA topoisomerase II alpha inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is daunorubicin hydrochloride?
daunorubicin hydrochloride (DAUNORUBICIN HYDROCHLORIDE) is a dna topoisomerase ii alpha inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for daunorubicin hydrochloride?
DAUNORUBICIN HYDROCHLORIDE is a marketed brand name for daunorubicin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of daunorubicin hydrochloride?
daunorubicin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.